Abstract 4997
Background
Hospice care aims to optimize the quality of life of patients and their families in the last phase of life by diminishing physical, psychological, social and spiritual suffering. Expectations are associated with patient satisfaction. A theoretical framework was used, distinguishing expectations with respect to process, structure and outcomes. The aim of the study is to explore expectations of hospice care of future hospice patients.
Methods
A generic qualitative study was performed from January to July 2018. Eleven patients with a life expectancy <1 year (‘surprise question’) were enrolled. In addition, two patient advocates were included to gain a broader view on expectations. Semi structured interviews were transcribed verbatim, analyzed by 2 researchers independently and results were discussed in the research team.
Results
The participants covered a range in gender, age, spiritual beliefs, living area, primary diagnosis, phase of palliation and knowledge on the topic. Participants expect to be admitted to hospice when death was imminent and dying at home becomes impossible. They expect a homelike environment and the ability to continue living like being at home. Participants are sure that caregivers in hospice care are loving and trustworthy. Without doubt patients expect them to provide appropriate care and treatment with the skills and knowledge necessary.
Conclusions
Hospices have the responsibility to ensure nuanced and balanced information on hospice care in the Dutch society to set realistic expectations. Information about the possibilities and aims of hospice care, including short stay admissions, respite care and support at home in collaboration with primary caregivers should be widespread to ensure timely and appropriate hospice care for all patients in need.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
ZonMw.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract